STUDY TITLE: TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT05343013

This is a Phase 2 study to measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy.

Status: Active, Recruiting

Key Eligibility Criteria

  • Patients with confirmed stage II-IV colon or rectal cancer
  • Patients must:
    • have completed all planned curative intent therapies that must include ≥ 3 months of oxaliplatin containing chemotherapy
    • have no radiographic evidence of disease within 28 days of positive ctDNA assay
    • have a ctDNA positive assay

Treatment

Drug: TAS-102 (Lonsurf), a thymidine phosphorylase inhibitor

Drug: Celecoxib, NSAID

Study Plan